First, life-sciences and biotech corporate originators who can move therapeutic or device relationships without a total FDA-client wipeout. Second, PE and venture partners covering healthcare, software and growth equity as sponsors deepen New England deployment. Third, IP partners with prosecution-plus-litigation ownership where District of Massachusetts dockets make diligence cleaner. Fourth, Corporate & M&A partners who can staff strategic and PE-backed deals through uneven windows.
NALP's 2025 data put Boston among the sharpest rebounds nationally: overall lateral hiring +156.0%, partner laterals +116.7%, associate laterals +138.9%, with 85.7% of reporting Boston offices posting at least a 16% increase. That public rebound matches what our Boston mandate telemetry records on the 18 closed partner searches of the last three years: roughly 55% of completed files were life sciences, biotech or IP, about 30% PE, venture or corporate, and the balance mixed-practice or platform-entry builds. Combining NALP's 2025 Boston partner rebound with that practice mix yields a derived read: more than half of the city's partner hiring energy is still biotech-adjacent even as pure PE office launches grab headlines.
Live confidential work (client-side) typically includes Am Law 50–100 single-partner adds in life sciences, PE platform builds for national firms deepening Boston, and IP partners for Hatch-Waxman or device dockets. Candidate-side interest is highest among partners whose originations have outgrown current platform credit, who need equity-path clarity, or who face a conflicts wall that a different firm can clear. Absolute volume has jumped; underwriting still decides who actually moves.